Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia

Blood

Volumn 122, Issue 14, 2013, Pages 2477-2486

  Audia, Sylvain ^a,b,c   Samson, Maxime ^a,b,c   Mahévas, Matthieu ^d   Ferrand, Christophe ^a   Trad, Malika ^a,c   Ciudad, Marion ^a,c   Gautheron, Alexandrine ^a,c   Seaphanh, Famky ^a,c   Leguy, Vanessa ^b   Berthier, Sabine ^b   Salles, Bruno ^e   Martin, Laurent ^a,b,c   Lorcerie, Bernard ^b,c   Ortega Deballon, Pablo ^b,c   Facy, Olivier ^b,c   Caillot, Denis ^b   Soudry Faure, Agnès ^b   Michel, Marc ^d   Godeau, Bertrand ^d   Larmonier, Nicolas ^f   Saas, Philippe ^a   Janikashvili, Nona ^a,c   Bonnotte, Bernard ^a,b,c,g   more..

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d University Hospital   (France)

^e University Hospital of Dijon ^*  (France)

^f UNIVERSITY OF ARIZONA   (United States)

^g France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 17; INTERLEUKIN 4; PERFORIN; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SPLEEN CELL; SPLENECTOMY; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REAL-TIME POLYMERASE CHAIN REACTION; SPLEEN; YOUNG ADULT;

EID: 84887677172     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491415     Document Type: Article

References (43)

1. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.
2. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194-201.
3. Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002;100(4):1388-1398.
4. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245-4254.
5. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930.
6. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103(7): 2645-2647.
7. Shimomura T, Fujimura K, Takafuta T, et al. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura. Br J Haematol. 1996;95(4):732-737.
8. Olsson B, Andersson PO, Jernås M, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
9. Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006; 76(5):427-431.
10. Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica. 2008;93(9): 1428-1430.
11. Olsson B, Jernås M, Wadenvik H. Increased plasma levels of granzymes in adult patients with chronic immune thrombocytopenia. Thromb Haemost. 2012;107(6):1182-1184.
12. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147-1150.
13. Audia S, Samson M, Guy J, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16): 4394-4400.
14. Li X, Zhong H, Bao W, et al. Defective regulatory B cell compartment in patients with immune thrombocytopenia. Blood. 2012;120(16): 3318-3325.
15. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704-706.
16. Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD81 T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605-611.
17. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369.
18. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
19. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
20. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-533.
21. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997; 97(2):336-339.
22. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-2634.
23. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672-1681.
24. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-2247.
25. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med. 2010;267(3):260-277.
26. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
27. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
28. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837.
29. Mahevas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432-442.
30. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5): 960-969.
31. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol. 2007;14(6):642-646.
32. Coito S, Sauce D, Duperrier A, et al. Retrovirusmediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. Stem Cells Dev. 2004;13(1):71-81.
33. Collette A, Cazenave PA, Pied S, Six A. New methods and software tools for high throughput CDR3 spectratyping. Application to T lymphocyte repertoire modifications during experimental malaria. J Immunol Methods. 2003;278(1-2): 105-116.
34. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42(6):455-500.
35. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4): 952-957.
36. Unsoeld H, Voehringer D, Krautwald S, Pircher H. Constitutive expression of CCR7 directs effector CD8 T cells into the splenic white pulp and impairs functional activity. J Immunol. 2004;173(5): 3013-3019.
37. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A. 2008;73(11):975-983.
38. Obar JJ, Lefrançois L. Memory CD81 T cell differentiation. Ann N Y Acad Sci. 2010;1183: 251-266.
39. Takata H, Takiguchi M. Three memory subsets of human CD81 T cells differently expressing three cytolytic effector molecules. J Immunol. 2006; 177(7):4330-4340.
40. Olsson B, Ridell B, Jernås M, Wadenvik H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol. 2012;91(2): 271-277.
41. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008; 112(4):1078-1084.
42. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD81 T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-1253.
43. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168(7):3675-3682.